Floatz logo

Pembrolizumab

Salivary Gland Cancer

OncoC4, Inc.monoclonal_antibodyPhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

8 Active assets in the Salivary Gland Cancer cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Genentech, Inc.
Phase 2BB
Carboplatin
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2BB
Cetuximab
Fox Chase Cancer Center
Phase 1/2B
Irinotecan
AIDS Malignancy Consortium
Phase 1/2B
Gdc-0449
Genentech, Inc.
Phase 2B

View all 42 →

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →